Introduction {#Sec1}
============

Multiple myeloma (MM) is a plasma cell neoplasm (PCN) representing the second most common hematopoietic malignancy and accounts for \~20% of all hematologic cancer related deaths in the United States^[@CR1]^. During the last decade there have been remarkable improvements in the treatment of patients with MM that have resulted in increased survival, including immunomodulatory compounds, proteasome inhibitors, and immunotherapeutic approaches such as monoclonal antibodies^[@CR2]^. Paralleling the advances in novel therapeutic strategies, characterization of the genomic complexities of MM have significantly improved with the implementation of next-generation sequencing (NGS), thus enabling the identification of novel single nucleotide variants (SNV), structural rearrangements and copy number abnormalities (CNA)^[@CR3]--[@CR11]^. Comprehensive genomic characterization studies such as the Multiple Myeloma Research Foundation (MMRF) CoMMpass Trial and other research studies are necessary for the discovery of novel variants of clinical significance that may lead to improved treatment approaches and prognostication strategies^[@CR12],[@CR13]^.

In contrast to the use of genome-wide NGS strategies employed in the research/investigational trial setting, most clinical genomics laboratories rely upon traditional cytogenetic methodologies such as conventional chromosome studies and fluorescence in situ hybridization (FISH) to characterize recurrent cytogenetic abnormalities of prognostic significance. High-risk cytogenetic abnormalities as defined by the Mayo Clinic mSMART 3.0 algorithm^[@CR14]^ include t(4;14), t(14;16), t(14;20) translocations, 17p deletions and 1q gains, while standard-risk cytogenetic abnormalities include hyperdiploidy (gains of odd-numbered chromosomes), t(11;14) and t(6;14) translocations^[@CR15],[@CR16]^. A limited number of laboratories evaluate for *MYC* and t(6;14) rearrangements, and detection of *IGK* and *IgL* rearrangements is not routinely performed in the clinical setting^[@CR15]^. Although FISH assays have high sensitivity, are relatively inexpensive compared to NGS techniques and provide input for risk stratification^[@CR17]^, several limitations exist. They allow for the interrogation of only the regions for which FISH probes are available and multiple FISH probes are needed in order to be comprehensive, with each probe requiring a resource-consuming validation. More importantly, FISH has the potential to miss cryptic abnormalities, including rearrangements that result in a position effect due to juxtaposition of enhancers near oncogenes^[@CR18]--[@CR22]^. Since many translocations identified in MM involve a position effect (i.e., IGH and *MYC*) with heterogeneous breakpoints^[@CR10],[@CR23],[@CR24]^ and some CNAs may be cryptic, we hypothesize that some clinical FISH probes used in the characterization of PCNs have a high rate of false negative FISH results.

To test this hypothesis, we evaluated the performance of a genome wide mate-pair sequencing (MPseq) assay in comparison to FISH panel testing for MM. Since MPseq utilizes long input DNA (2--5 Kb) followed by circularization and fragmentation to the size of paired-end fragments (200--500 bp) that are sequenced at reduced depth, this assay is designed to detect structural rearrangements and CNAs throughout the genome resulting in a cost-effective strategy amenable to a clinical genomics laboratory. Furthermore, as MPseq has higher resolution than FISH and is not limited to specific genomic footprints for interrogation, this assay could provide an alternative technique to comprehensively detect structural rearrangements and CNAs in a single assay. Herein we describe the performance, along with the added clinical utility, of MPseq in 70 samples previously characterized by FISH to detect chromosome rearrangements and CNAs in patients with a PCN.

Methods {#Sec2}
=======

Patient samples {#Sec3}
---------------

All samples were referred to the Mayo Clinic Genomics Laboratory as part of routine clinical testing and further evaluated by MPseq as part of a Mayo Clinic Institutional Review Board approved study. There were multiple sources of samples obtained either from fresh or frozen whole bone marrow (BM), or from fixed cell pellets (FCP) from an abnormal BM chromosome study. Some specimens had undergone plasma cell enrichment from fresh whole BM that was either flow sorted or subjected to CD138+ magnetic-enrichment from patients that had an abnormal plasma cell FISH result. Additional methodology, including conventional chromosome analysis and flow cytometry are included in supplemental data.

Fluorescence in situ hybridization {#Sec4}
----------------------------------

Plasma cell proliferative disorder FISH (PCPDF) of immunoglobulin (cIg)-stained positive PCs studies were performed as previously described^[@CR25]^ using the following probes to detect primary and secondary MM abnormalities: monosomy 13 or 13q deletion (Abbott Molecular, Abbott Park, IL), monosomy 17 or *TP53* deletion (Abbott Molecular), trisomy 3, 7, 9 or 15 (Abbott Molecular), 1q gain (in house, custom developed), *MYC* rearrangement (Abbott Molecular), IGH rearrangement (in house, custom developed), t(11;14) *CCND1/IGH* (Abbott Molecular), t(4;14)(p16.3;q32) *FGFR3*/*IGH* (Abbott Molecular), t(6;14)(p21;q32) *CCND3*/*IGH* (Abbott Molecular), t(14;16)(q32;q23) *IGH*/*MAF* (Abbott Molecular), and t(14;20)(q32;q12) *IGH*/*MAFB* (Abbott Molecular). The PCN FISH panel is indicated in supplemental Table [1](#MOESM1){ref-type="media"} with footprints and probe source shown in supplemental Table [2](#MOESM1){ref-type="media"}.

Plasma cell enrichment {#Sec5}
----------------------

BM cells (20 × 10^6^) were lysed in ACK lysis buffer for 5 min. This was followed by 2 wash steps in PBS (lyse-wash procedure) and the cell pellet was re-suspended in 3% BSA/PBS. 10 × 10^6^ cells were then incubated for 15 min with the following antibodies: CD19-PerCP 5.5 (clone SJ25C1, BD Biosciences), CD38-APC (clone REA671, Miltenyi Biotec), CD45-BB515 (clone HI30, BD Biosciences), CD56-PE-Cy7 (clone NCAM16.2, BD Biosciences), CD138-BV421 (clone MI15, BD Biosciences), and CD319-PE (clone REA150, Miltenyi Biotec). The specimen was centrifuged and re-suspended in 1.5 mL of PBS. Sorting was performed on BD FACSMelody cell sorter (BD Biosciences, San Jose, CA). Sorting streams were defined for each case separately, using gates to include CD138-positive, CD319-positive, CD38-bright, CD56-positive and/or CD45-negative plasma cells, and separate them from normal plasma cells. A minimum of 2 × 10^5^ cells were collected, with the purity of at least 95%, verified by Kaluza software (Beckman Coulter Life Sciences, Indianapolis, IN). In some cases, plasma cells were separated by positive selection using CD138-coated magnetic beads (MACS; Miltenyi Biotec, CA) in a RoboSep system (STEMCELL Technology, Canada) as described in Jang et al.^[@CR26]^.

DNA extraction and library preparation {#Sec6}
--------------------------------------

DNA extraction and mate pair library preparation methods have been previously described^[@CR18],[@CR27],[@CR28]^. Briefly, DNA was isolated using either the Qiagen Puregene extraction kit (for samples \< 2 mL), Autopure LS Automated high quality DNA extraction (for samples \> 2 mL) or the QIAmp Tissue kit for fixed cell pellet samples. DNA was processed using the Illumina Nextera Mate Pair library preparation kit and sequenced on the Illumina HiSeq 2500 in rapid run mode as described in Aypar, et al.^[@CR18]^. Pooled libraries were hybridized onto a flow cell (2 samples per lane) and sequenced using 101-basepair reads and paired end sequencing.

Structural variant bioinformatics pipeline and visualization {#Sec7}
------------------------------------------------------------

The sequencing data was analyzed for the detection of structural variants (SVs), which are large genomic changes (\>30Kb) that involve breakpoint junctions and/or CNAs. The sequencing data was mapped to the reference genome (GRCh38) using BIMA^[@CR29]^ and the output was analyzed using SVAtools. This set of algorithms can detect and report the breakpoint locations of both junctions and CNAs at high resolution and accuracy (Schematic in supplemental Fig. [1](#MOESM2){ref-type="media"})^[@CR18],[@CR27],[@CR28]^. Junctions and CNVs were graphically illustrated using genome, junction and region plots as previously described^[@CR18],[@CR27],[@CR30]^.

Results {#Sec8}
=======

Patient characteristics {#Sec9}
-----------------------

A total of 70 cases referred to the Mayo Clinic Genomics Laboratory for routine clinical PCN FISH testing were selected for further evaluation by MPseq (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} and supplemental Table [3](#MOESM1){ref-type="media"}). Criteria for inclusion included the type of primary cytogenetic abnormality to ensure representation of each recurring rearrangement and sample source to evaluate various methods of sample attainment, including PC enrichment (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}). The median age was 66 years (range 42--88) demonstrating male predominance with a 1.3:1 (M:F) ratio. Fifty-seven cases (81.4%) had either a diagnosis of MM (*N* = 35) or a reason for referral (RFR) of MM or PCN indicated at the time of clinical testing (*N* = 22) (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}). Of thirty-five cases with complete clinical data, 13 (37.1%) were newly diagnosed (ND) and 22 (62.9%) had relapsed and/or refractory disease (RR).Table 1Patient cohort.SiteSexAge (years)Dx or RFR^a^ND RR% PCLight chainSample typePrimary abnormality (FISH)FISH1MCLM77MM^a^U85KappaFCP11;14nuc ish(MYC,RB1,LAMP1)x1,(CCND1-XT,IGH-XT)x3(CCND1-XT con IGH-XTx2)2MAYOF65MMND23LambdaSort11;14nuc ish(TP73x2,1q22x3),(5′MYCx2,3'MYCx1)(5′MYC con 3′MYCx1),(CCND1-XT,IGH-XT)x3(CCND1-XT con IGH-XTx2)3MCLF70PCN^a^U19KappaSort11;14nuc ish(MYCx2)(5′MYC sep 3′MYCx1),(CCND1-XT,IGH-XT)x3(CCND1-XT con IGH-XTx2)/(CCND1-XT,IGH-XT)x4(CCND1-XT con IGH-XTx3),(RB1,LAMP1)x1,(TP53x1,D17Z1x2)4MAYOM71MMND37LambdaSort11;14nuc ish(TP73x2,1q22x3),(CCND1-XT,IGH-XT)x4--5(CCND1-XT con IGH-XTx3--4)/(CCND1-XTx1,CCND1-XT amp,IGH-XTx1,IGH-XT amp)(CCND1-XT amp con IGH-XT amp),(RB1,LAMP1)x15MCLM69MM^a^U50KappaSort11;14nuc ish(TP73x2,1q22x5),(D3Z1,D9Z1,D15Z4)x3,(CCND1-XT,IGH-XT)x3(CCND1-XT con IGH-XTx2),(RB1,LAMP1)x16MAYOM63MMRR28KappaSort11;14nuc ish(TP73x1,1q22x3--4)/(TP73x2,1q22x6),(D3Z1,D7Z1,D9Z1,D15Z4)x4,(5′MYCx3,3′MYCx2)(5′MYC con 3′MYCx2)/(5′MYCx6,3′MYCx4)(5′MYC con 3′MYCx4),(CCND1-XT,IGH-XT)x3(CCND1-XT con IGHx2)/(CCND1-XT,IGH-XT)x4(CCND1-XT con IGHx3)/(CCND1-XT,IGH-XT)x5(CCND1-XT con IGHx4),(TP53x1,D17Z1x2)7MAYOF83MMND37KappaSort11;14nuc ish(TP73x2,1q22x3),(CCND1-XT,IGH-XT)x3(CCND1-XT con IGH-XTx2)8MCLM63MM^a^U73KappaFresh11;14nuc ish(CCND1-XTx3,IGH-XTx2)(CCND1-XT con IGHx2)/(CCND1-XTx5,IGH-XTx4)(CCND1-XT con IGHx4),(TP53x1,D17Z1x2)9MCLM69MMU65KappaFresh11;14nuc ish(TP73,1q22,MYC,RB1,LAMP1,TP53,D17Z1)x4,(D3Z1,D7Z1,D9Z1,D15Z4)x3--4, (CCND1-XTx6,IGH-XTx7)(CCND1-XT con IGH-XTx4)10MCLM77MM^a^U68KappaFresh11;14nuc ish(CCND1-XT,IGH-XT)x4(CCND1-XT con IGH-XTx3),(TP53x1,D17Z1x2)11MAYOM58PCLRR58LambdaFrozen11;14nuc ish(CCND1-XT,IGH-XT)x4(CCND1-XT con IGH-XTx3),(RB1x1,LAMP1x2)12MAYOF77MMND50KappaFrozen11;14nuc ish(CCND1-XTx3,IGH-XTx2)(CCND1-XT con IGH-XTx1)13MAYOF59ALND5LambdaCD138+11;14nuc ish(CCND1-XTx3),(IGH-XTx3),(CCND1-XT con IGH-XTx2)14MAYOF63PCPDU5LambdaCD138+11;14nuc ish(CCND1-XTx3,IGH-XTx2)(CCND1-XT con IGH-XTx1),(RB1,LAMP1)x115MAYOF54MMND45KappaCD138+11;14nuc ish(CCND1-XTx2),(IGH-XTx2),(CCND1-XT con IGH-XTx1)/(CCND1-XTx2),(IGH-XTx3),(CCND1-XT con IGH-XTx1)16MCLF67IgA gammopathy^a^U40LambdaFCP4;14nuc ish(TP73x2,1q22x3--4),(FGFR3,IGH)x3(FGFR3 con IGHx2),(5′MYCx3,3′MYCx2)(5′MYC con 3′MYCx2),(RB1,LAMP1)x117MAYOM75MMRR13KappaSort4;14nuc ish(TP73x2,1q22x3),(FGFR3,IGH)x3(FGFR3 con IGHx2),(MYCx2)(5′MYC con 3′MYCx1),(RB1,LAMP1)x118MCLM73MM^a^U34KappaSort4;14nuc ish(TP73x2,1q22x3),(FGFR3,IGH)x3(FGFR3 con IGHx2),(RB1,LAMP1)x119MCLM68Monoclonal gammopathy^a^U20LambdaSort4;14nuc ish(TP73x2,1q22x3),(D3Z1,D9Z1,D15Z4)x3,(FGFR3,IGH)x3(FGFR3 con IGHx2),(RB1,LAMP1)x120MCLM72PCLU70KappaFresh4;14nuc ish(TP73x2,1q22x4),(FGFR3,IGH)x3(FGFR3 con IGHx2),(MYCx2)(5′MYC sep 3′MYCx1),(RB1,LAMP1)x1,(TP53x1,D17Z1x2)21MCLM42MM^a^U89KappaFresh4;14nuc ish(TP73x2,1q22x3),(FGFR3,IGH)x3(FGFR3 con IGHx2),(MYCx4)(5′MYC sep 3′MYCx1),(RB1,LAMP1)x1,(TP53x2,D17Z1x1)22MAYOM57MMRR41KappaFresh4;14nuc ish(TP73x2,1q22x3),(FGFR3,IGH)x3(FGFR3 con IGHx2),(5'MYCx2,3′MYCx1)(5′MYC con 3′MYCx1),(RB1,LAMP1)x1,(TP53x1,D17Z1x2)/(TP73x4,1q22x6),(D3Z1x3),(FGFR3,IGH)x4(FGFR3 con IGHx3)/(FGFR3,IGH)x5(FGFR3 con IGHx4),(D7Z1,D9Z1,D15Z4)x3--4,(5′MYCx4,3′MYCx2)(5'MYC con 3'MYCx2),(CCND1-XTx4),(RB1,LAMP1)x2,(TP53x2,D17Z1x4)23MAYOM78MMRR77LambdaFrozen4;14nuc ish(TP73x2,1q22x3),(FGFR3,IGH)x2(FGFR3 con IGHx1),(RB1,LAMP1)x1,(TP53x1,D17Z1x2)24MCLM63MM^a^U13KappaSort14;16nuc ish(TP73x2,1q22x3),(D9Z1,RB1,LAMP1)x1,(IGHx4,MAFx3)(IGH con MAFx2)25MAYOF60MMND31KappaSort14;16nuc ish(TP73x2,1q22x3),(RB1,LAMP1)x1,(IGHx3,MAFx2)(IGH con MAFx2)26MAYOF80MMRR25KappaCD138+14;16nuc ish(D3Z1,D9Z1,p53,D17Z1)x3/(Rb1,LAMP1,D15Z4)x1/(IGHx2),(c-MAFx3),(IGH con c-MAFx1)27MAYOF67MMND60KappaCD138+14;16nuc ish(IGHx3),(MAFx3),(IGH con MAFx2)28MCLM75MM^a^U27KappaFCP14;20nuc ish(TP73x4,1q22x6--8),(5′MYC,3′MYC)x4(5′MYC con 3′MYCx2),(RB1,LAMP1)x2,(IGHx6,MAFBx4)(IGH con MAFBx2),(TP53,D17Z1)x429MCLM88MM^a^U56KappaFCP14;20nuc ish(MAFBx2,IGHx3)(MAFB con IGHx2),(RB1,LAMP1)x130MCLF65R/O MM^a^U63KappaFresh14;20nuc ish(MYCx2)(5′MYC sep 3′MYCx1),(RB1,LAMP1)x1,(IGH,MAFB)x3(IGH con MAFBx2)/(IGHx4,MAFBx3)(IGH con MAFBx2)31MAYOF74MMND5KappaFresh14;20ish(TP73x3,1q22x6),(D3Z1,D9Z1,D15Z4,TP53,D17Z1)x4,(D7Z1x5),(MYCx3--4),(CCND1-XTx4--5),(RB1,LAMP1)x2,(IGHx3,MAFBx4)(IGH con MAFBx1)32MCLM74MM^a^UN/AN/AFCP6;14nuc ish(TP73,1q22)x3,(CCND3x2,IGHx1)(CCND3 con IGHx1),(RB1,LAMP1)x1,(TP53x1,D17Z1x2)33MCLM51R/O MM, hypercalcemia, renal failure^a^UN/AN/AFCP6;1484,XX,der(Y;16)(q10;p10)x2,i(1)(q10)x2,--2,--4,--4,t(6;14)(p21.1;q32)x2,−8,t(8;14) (q24.1;q32),−10,−11,der(14)t(8;14)^[@CR6]^/46,XY^[@CR14]^ nuc ish,(CCND3x2,IGHx1)(CCND3 con IGHx1) only *CCND3/IGH* FISH performed on FCP sample34MCLF58MM^a^U21KappaFCPHyper + IGH sepnuc ish(TP73x2,1q22x3),(D7Z1,MYC)x3,(RB1,LAMP1,D15Z4)x1,(3′IGHx2,5'IGHx1)(3′IGH con 5′IGHx1)/(IGHx2)(3'IGH sep 5′IGHx1),(TP53x1,D17Z1x2)35MCLF54MM^a^U31KappaFCPHyper + IGH sepnuc ish(D3Z1,D9Z1,D15Z4)x3,(FGFR3,CCND3,MAF,MAFB)x1,(MYCx2)(5′MYC sep 3′MYCx1),(CCND1-XTx4--5),(3′IGHx3,5′IGHx2)(3′IGH con 5′IGHx2)/(IGHx3)(3′IGH sep 5′IGHx2)36MAYOM82MMRR7LambdaSortHyper + IGH sepnuc ish(TP73x2,1q22x3),(CCND3,D7Z1,D9Z1)x3,(3′IGHx2,5′IGHx1)(3′IGH con 5′IGHx1)37MAYOM61MMRR27KappaSortHyper + IGH sepnuc ish(5′MYCx2,3′MYCx1)(5′MYC con3′MYCx1)/(D9Z1x3--4)/(CCND1-XTx3)/(3′IGHx2,5′IGHx1)(3′IGH con 5′IGHx1)/(3′IGHx3,5′IGHx2)(3′IGH con 5′IGHx2)38MAYOF58MMRR11LambdaSortHyper + IGH sepnuc ish(TP73x2,1q22x4--5),(D3Z1,D7Z1,D9Z1,CCND1-XT,TP53,D17Z1)x3,(RB1x1,LAMP1x2),(3′IGHx2,5'IGHx1)(3′IGH con 5'IGHx1)39MCLM64MMU20KappaFreshHyper + IGH sepnuc ish(TP73x2,1q22x3),(MYC,D9Z1,CCND1-XT,D15Z4)x3,(3′IGHx3,5′IGHx2)(3′IGH con 5′IGHx2)40MCLM80MMU81LambdaFreshHyper + IGH sepnuc ish(TP73x2,1q22x3),(FGFR3,MAF,MAFB)x1,(CCND3,D9Z1,D15Z4)x3,(3′IGHx3,5′IGHx2)(3′IGH con 5′IGHx2),(TP53x1,D17Z1x2)41MCLM60MM^a^U98KappaFreshHyper + IGH sepnuc ish(TP73x3,1q22x2),(D3Z1,CCND3,CCND1-XT,D15Z4)x3,(MYCx2)(5′MYC sep 3′MYCx1),(RB1,LAMP1,MAF)x1,(3′IGHx4--5,5′IGHx4)(3'IGH con 5′IGHx3),(TP53x1,D17Z1x2)42MAYOM70MMRR19KappaSortHyper + IGH sepnuc ish(D3Z1,D7Z1,D9Z1,D15Z4)x3,(5′MYCx3,3′MYCx2)(5′MYC con 3′MYCx2),(CCND1-XT amp),(3′IGHx3,5′IGHx2)(3′IGH con 5′IGHx2)43MAYOF56PCPDU4IndeterminateSortHypernuc ish(CCND1-XTx3),(RB1,LAMP1)x144MAYOM67MMRR12KappaSortHypernuc ish(CCND1-XTx3),(RB1,LAMP1,IGH,TP53,D17Z1)x145MCLM76MM^a^U14KappaSortHypernuc ish(TP73x2,1q22x3),(D3Z1,D9Z1,CCND1-XT)x3,(MYCx2)(5′MYC sep 3′MYCx1),(D15Z4x3--4)46MAYOM66MMND19KappaSortHypernuc ish(TP73x2,1q22x3),(D3Z1,MYC,CCND1-XT,D15Z4)x3,(D9Z1x3--4)47MAYOM72MMND10KappaSortHypernuc ish(TP73x2,1q22x3),(D3Z1,MYC)x3,(D7Z1,D9Z1)x3--4,(RB1,LAMP1,IGH,D15Z4)x148MCLF77Anemia, coagulation defect^a^U10KappaSortHypernuc ish(TP73x2,1q22x3),(D7Z1,D9Z1,D15Z4)x3,(RB1x1,LAMP1x2)49MCLM73R/O MM^a^U35KappaSortHypernuc ish(TP73x2,1q22x3),(D3Z1,D7Z1,D9Z1,CCND1-XT)x3,(D15Z4x3--4)50MCLF64MM^a^U48KappaFreshHypernuc ish(CCND1-XTx4),(IGHx3),(MAFx1)51MAYOF49MMRR84LambdaFreshHypernuc ish(TP73x2,1q22x3--4),(D3Z1,D9Z1)x3,(5′MYCx4--5,3′MYCx1)(5'MYC con 3′MYCx1),(CCND1-XT,D15Z4)x3--4,(TP53x1,D17Z1x2)52MCLF75PCPD^a^U73LambdaFreshHypernuc ish(D3Z1,D7Z1,D9Z1)x3,(RB1,LAMP1,IGH)x1,(TP53x1,D17Z1x2)53MCLF66MM^a^U52KappaFreshHypernuc ish(D3Z1,D9Z1,CCND1-XT,D15Z4)x354MCLM65MM^a^U52LambdaFreshHypernuc ish(TP73x2,1q22x3--4),(D3Z1,D7Z1,D9Z1,IGH,D15Z4,TP53,D17Z1)x3,(CCND1-XTx3--4),(RB1,LAMP1)x1/(RB1x2,LAMP1x1)55MCLM57Solitary plasmacytomaU99KappaFreshHypernuc ish(TP73x2,1q22x3),(D3Z1,D9Z1)x3,(CCND1-XT,D15Z4)x3--4,(RB1x1,LAMP1x2)56MCLF56MM^a^U34KappaFreshHypernuc ish(D3Z1,D7Z1,CCND1-XT)x3,(D9Z1,D15Z4)x3--457MAYOM61MMRR55KappaFrozenHypernuc ish(TP73x2,1q22x3),(D3Z1,D7Z1,D15Z4)x3,(D9Z1)x3--4,(RB1x1,LAMP1x2)58MAYOM59MMRR79IndeterminateFrozenHypernuc ish(TP73x2,1q22x3),(D3Z1,CCND1-XT)x359MAYOM74MMRR60KappaCD138+Hypernuc ish(D3Z1,D7Z1,D9Z1,D15Z4)x360MAYOM53MMND90KappaCD138+Hypernuc ish(D3Z1,D9Z1,CCND1-XT,D15Z4),(IGH)x161MAYOF61MMRR25KappaCD138+Hypernuc ish(D3Z1,D7Z1,D9Z1,CCND1)x3/(Rb1,LAMP1)x1/(D15Z4x3--4) nuc ish(TP73x2,CKS1Bx3),(MYCx3)62MAYOM48MMRR75LambdaCD138+Hypernuc ish(D3Z1,D9Z1,CCND1-XT,D15Z4)x3/(IGHx1)63MAYOF61MMRR5KappaCD138+Hypernuc ish(D9Z1,CCND1-XT,D15Z4)x364MAYOF48MMRR70KappaCD138+Hypernuc ish(D3Z1,D7Z1,CCND1-XT)x3/(D9Z1,D15Z4)x3--465MAYOF66MMRR25LambdaCD138+Hypernuc ish(CCND1-XT)x366MCLF70MMU39LambdaSortTetraploidnuc ish(TP73x2,1q22x4--6),(D3Z1,TP53,D17Z1)x4,(D7Z1,MYC,D9Z1,CCND1-XT,RB1,LAMP1,IGH,D15Z4)x3--467MCLM74Gammopathy^a^U36LambdaSortMonosomy 13/14nuc ish(TP73x1,1q22x2),(RB1,LAMP1,IGH)x168MAYOM58MMND15LambdaCD138+Monosomy 15nuc ish(D15Z4x1)69MAYOF62ALRR5LambdaCD138+Monosomy 15nuc ish(D15Z4x1)70MAYOF68ALRR9KappaCD138+NormalNormalCohort of 70 patients evaluated. *MCL* Mayo Clinic Laboratories, *F* female, *M* male, *Dx* diagnosis, *RFR* reason for referral, *AL* amyloidosis, *ND* newly diagnosis, *RR* relapsed/refractory, *U* unknown status. ^a^Indicates only RFR is available. % PC from flow cytometryOnly abnormal FISH results are indicated in the ISCNTable 2Patient characteristicsTotal (*N* = 70)Characteristic*N* (%)SexMale40 (57.1)Female30 (42.9)AgeMedian66 yearsRange42--88 years40--494 (5.7)50--5914 (20.0)60--6926 (37.1)70--7921 (30.0)80--895 (7.1)Diagnosis or RFRMM, PCN diagnosis or RFR57 (81.4)Amyloidosis3 (4.3)Plasma cell leukemia2 (2.9)Plasma cell proliferative disorder3 (4.3)Other5 (7.1)SiteMayo Clinic-local37 (52.9)Mayo Clinic Laboratories-outside33 (47.1)PC percentage (N = 68)Median35.5%Range4--99%4--1919 (27.9)20--3919 (27.9)40--5911 (16.2)60--7912 (17.6)80--997 (10.3)Sample typeNo enrichment31 (44.3)Fixed cell pellet (FCP)8 (11.4) median PCs (35.5)Fresh sample18 (25.7) median PCs (66.5)Frozen sample5 (7.1) median PCs (58.0)Enrichment39 (55.7)Flow sorting24 (34.3) median PCs (19.5)CD138+ magnetic15 (21.4) median PCs (25.0)Light chainKappa46 (65.7)Lambda20 (28.6)Indeterminate or unknown4 (5.7)Primary cytogenetic abnormalityt(11;14)15 (21.4)t(4;14)8 (11.4)t(14;16)4 (5.7)t(14;20)4 (5.7)t(6;14)2 (2.9)Hyperdiploid only23 (32.9)Hyperdiploid with an unknown IGH rearrangement9 (12.9)Tetraploid without primary abnormality1 (1.4)Monosomy 13/14 alone1 (1.4)Monosomy 15 alone2 (2.9)Normal1 (1.4)Conventional chromosome studyNot performed28 (40.0)Performed42 (60.0)Normal or loss of Y27 (38.6 of total, 64.3 of performed)Abnormal with PC abnormalities14 (20.0 of total, 33.3 of performed)Abnormal with non-PC abnormalities1 (1.4 of total, 2.4 of performed)Patient characteristics of the 70 patients within the cohort evaluated

MM abnormalities identified by FISH {#Sec10}
-----------------------------------

Recurrent primary MM cytogenetic abnormalities identified by FISH in samples 1--65 were t(11;14) (21.4%), t(4;14) (11.4%), t(14;16) (5.7%), t(14;20) (5.7%), t(6;14) (2.9%), and hyperdiploidy (45.7%) either without an IGH rearrangement (32.9%) or with an IGH rearrangement that did not involve *CCND1*, *FGFR3*, *MAF*, *MAFB* or *CCND3* (12.9%) (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}). Five samples (cases 66--70) had undefined primary abnormalities including one case of tetrapoloidy with a relative 1q gain, one case with monosomies 13 and 14, two cases with monosomy 15 by FISH and a single case with normal FISH results in a patient with a diagnosis of amyloidosis (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}). Conventional chromosome studies were performed on 42 (60.0%) cases and an abnormal PC clone was identified in 33.3% of the cases with chromosome studies performed (Supplemental Table [3](#MOESM1){ref-type="media"}).

We have previously determined tumor content requirements for MPseq requiring 10% tumor for the detection of structural rearrangements and 25% tumor for the detection of CNAs^[@CR18]^. Since variable and sometimes low clonal PC percentages can be identified in the BM aspirates of patients with NDMM^[@CR31]^, we performed two enrichment strategies for samples with low PCs including magnetic enrichment or flow sorting. For some samples, no enrichment was performed. Thirty-nine (55.7%) samples with a median 23.0% PCs were subjected to either flow sorting (*N* = 24) or CD138 + magnetic bead for PC enrichment (*N* = 15). For the remaining 31 samples (44.3%) with a median 58% PC, no PC enrichment was performed.

Identification of recurrent, primary cytogenetic abnormalities using MPseq {#Sec11}
--------------------------------------------------------------------------

To determine the accuracy of MPseq in comparison to our PCN FISH panel (Supplemental Table [1](#MOESM1){ref-type="media"}) in the detection of recurrent, primary MM abnormalities (IGH rearrangement and/or hyperdiploidy), we analyzed DNA extracted from either a fixed cell pellet (FCP) from a chromosome study (*n* = 8), from fresh (*n* = 18) or frozen (*n* = 5) BM aspirates or from fresh BM specimens that had been flow sorted (*n* = 24) or subjected to CD138 + magnetic enrichment (*n* = 15) (Supplemental Fig. [1](#MOESM2){ref-type="media"}, Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}). For samples 1--65, MPseq confirmed the primary abnormality identified by FISH in each case demonstrating 100% concordance between both assays for the classification of recurrent, primary cytogenetic abnormalities (Fig. [1](#Fig1){ref-type="fig"}). For those cases without evidence of a recurrent, primary abnormality (samples 66--69), MPseq did not identify tetraploidy in case 66 and monosomy 15 in cases 68--69, but identified monosomies 13 and 14 in case 67 and confirmed no recurrent abnormality in case 70 with normal FISH results. As a negative control, no recurrent primary MM abnormalities (MM specific IGH rearrangements and/or hyperdiploidy with gains of odd numbered chromosomes) were identified by MPseq in a previously described cohort of 88 patients with a reason for referral of acute myeloid leukemia (data not shown)^[@CR18]^.Fig. 1Concordance between MPseq and FISH.In bold indicates primary cytogenetic abnormalities. Cytogenetic risk applied to all cases: H: high and S:standard. ND: Newly diagnosed, RR: relapsed/refractory. For case 33, there was no FISH for MYC BAP, but detection of t(8;14) and t(6;14) was achieved using chromosome studies and *CCND3/IGH* rearrangement confirmed by FISH. For case 37, there was a history of trisomies 9,11,15, and IGH separation in an older sample. For cases 61 and 65 there was evidence of hyperdiploidy by FISH in older samples. Highlighted in yellow is a single case with a difference in cytogenetic risk between MPseq and FISH.

Comparison of MPseq to FISH for detection of recurrent, secondary abnormalities {#Sec12}
-------------------------------------------------------------------------------

For each primary and secondary abnormality that was identified by either MPseq or FISH, 40 cases (57.1%) displayed concordance between FISH and MPseq. Thirty cases (42.9%) displayed at least one instance of discordance between FISH and MPseq (Figs. [1](#Fig1){ref-type="fig"}, [2a](#Fig2){ref-type="fig"}). Nine of these 30 discordant cases had abnormalities detected by FISH that went undetected by MPseq (Figs. [1](#Fig1){ref-type="fig"}, [2a](#Fig2){ref-type="fig"}, "FISH advantage"). Of these nine cases, six had a tetraploid clone that was not detectable by MPseq and in three cases MPseq failed to detect CNAs that were identified by FISH (trisomy 3, trisomy 9 and 1q gain). In six cases, FISH identified a CNA involving chromosome 15 that was not confirmed by MPseq. These abnormalities included monosomy 15 identified by FISH without evidence of monosomy 15 by MPseq (cases 26, 47, 68, 69), or one (case 34) or two (case 52) copies of chromosomes 15 identified by FISH in cases with trisomy 15 identified by MPseq (Figs. [1](#Fig1){ref-type="fig"}, [2a](#Fig2){ref-type="fig"}). In contrast, 19 of the 30 discordant cases had abnormalities detected by MPseq that went undetected by FISH (Figs. [1](#Fig1){ref-type="fig"}, [2a](#Fig2){ref-type="fig"}, "MPseq advantage"). Of these 19 cases, 17 were *MYC* rearrangements and two were 17p deletions (cases 4 and 21), including a 17p translocation involving the *TP53* gene in one case (Figs. [1](#Fig1){ref-type="fig"}, [2a](#Fig2){ref-type="fig"}).Fig. 2Discordance summary and *MYC* breakpoint locations.**a** Total number of cases with evidence of MPseq advantage, FISH advantage and polymorphism of chromosome 15. **b** The location of breakpoints in the *MYC* locus across all cases are depicted as vertical lines (black if the *MYC* alteration was detected by FISH, light gray if it was not tested by FISH, and red if it was undetected by FISH). In cases where multiple breakpoints were found in the *MYC* locus, the lines are connected by an arc. The locations of the *MYC* BAP probes used for FISH detection are shown at the top (5′ in red, 3′ in green) and gene locations are shown in the middle (forward strand in light blue, reverse strand in pink).

Increased detection rate of *MYC* rearrangements by MPseq {#Sec13}
---------------------------------------------------------

From 70 total cases, we identified 36 cases (51.4%) that displayed a *MYC* rearrangement by MPseq (Fig. [1](#Fig1){ref-type="fig"}). Of these 36 cases, 34 had FISH data evaluating the *MYC* locus. Seventeen cases (50.0% of *MYC* abnormal group with FISH results) displayed a false negative *MYC* FISH result where a *MYC* rearrangement was identified by MPseq, but was negative by FISH (Fig. [1](#Fig1){ref-type="fig"}). The most common partner gene/enhancer segment identified were IGH (*n* = 7), *FAM46C* (n = 5), IGK (*n* = 4), *NSMCE2* (*n* = 4), *TXNDC5* (*n* = 4) and *IGL* (*n* = 4) (Table [3](#Tab3){ref-type="table"}). Of the 36 *MYC* rearrangements, multiple mechanisms resulting in positioning of *MYC* near enhancer sequences including small insertions, inversions, simple, balanced or complex translocations were identified (Table [3](#Tab3){ref-type="table"}). The most common method of rearrangement identified in 15 cases included a small insertion of enhancer sequences near the *MYC* gene or, alternately, the insertion of *MYC* near enhancer sequences. These insertions typically involve the duplication of genetic material of similar size at both the source location and the insertion location, whereby the source DNA is inserted between flanking duplications at the insertion location^[@CR32]^ (Fig. [2b](#Fig2){ref-type="fig"}). Thirteen of these 15 insertion cases co-occurred with hyperdiploidy (hyperdiploidy only or hyperdiploidy with IGH separation) and two of these cases were identified by FISH studies. Of the 17 *MYC* cases that were missed by FISH, 11 represented these small insertions (Table [3](#Tab3){ref-type="table"}).Table 3Genetic information of secondary alterations involving *MYC*.For each case where a secondary alteration involving *MYC* was found, the relevant genomic information is provided for the junction(s). The case column is the case number. The FISH column indicates whether or not the *MYC* FISH test detected the secondary alteration (dark gray--detected by both FISH, light gray--detected by MPseq but not tested by FISH and red--detected by MPseq only). The type column is the type of alteration involved with *MYC* classified as either a balanced event, a tandem duplication, a translocation, an inversion, part of an amplification, part of a small insertion motif, a complex event, or ND where it was not possible to definitively classify the alteration. The Junction column is the number of junctions involved directly in the alteration, either 1 or 2. The Chr Partner and Pos Partner columns are the chromosome and position location (GRCh38) of the partner breakpoints that are part of alteration. The Pos *MYC* and *MYC* Loc columns give the position of the breakpoint in the *MYC* locus and whether the alteration is to the left, right, or encompassing (L, R, or E) the *MYC* gene, respectively. The Gene Pair column is the gene that is found at or near the partner breakpoint location. The Primary column is the primary alteration for the case

Detection of additional genomic alterations by MPseq that are not evaluated by FISH {#Sec14}
-----------------------------------------------------------------------------------

We next evaluated for the presence of rearrangements involving non-recurrent IGH MM partners (excluding *CCND1*, *FGFR3*, *MAF*, *MAFB* or *CCND3*) and the IGK and IGL loci by MPSeq. There were 19 additional IGH rearrangements identified in 18 cases (25.7% of cohort) with partner chromosomes at 8q24.21 (*MYC*) (*n* = 7) as the only recurrent rearrangement (Table [4](#Tab4){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}). Of the nine cases classified as "hyperdiploidy with IGH separation", an IGH partner was identified in six cases, while the other three cases had a loss within the IGH locus. Two cases (cases 50 and 54) classified as hyperdiploidy without an IGH rearrangement to one of the common partner chromosomes had the "small insertion" type of *MYC/IGH* rearrangement (Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}). There were three cases with a *CCND1* rearrangement to a locus other than IGH (IGK/*CCND1* in case 43, IGL/*CCND1* in case 4 and *BRINP3*/*CCND1* in case 57) that had additional copies of *CCND1* observed by FISH in case 4 and 43. FISH for *CCND1* was not performed in case 57 and in case 4, the signal pattern for *CCND1* was scored as amplification (Table [4](#Tab4){ref-type="table"}, Figs. [1](#Fig1){ref-type="fig"}, [3](#Fig3){ref-type="fig"}).Table 4IGH, IGK, and IGL partner genes.CaseIGH partner chromosomePutative gene targetPrimary abnormality514q24.3*BATF*11;14619p13.2*TYK2*11;14811q14.1*RAB39*11;1491p35.3*PTPRU*11;1498q24.21*MYC*11;141020q11.21*COMMD7*11;141122q13.1*POLR2F*11;14152p24.3*MYCN*11;14208q24.21*MYC*4;14305p15.33*TERT*14;20338q24.21*MYC*6;14347q32.1*Unknown*Hyper + IGH sep36Xq32.33*MTMR1*Hyper + IGH sep3714q24.3*DPF3*Hyper + IGH sep408q24.21*MYC*Hyper + IGH sep419p13.2*PAX5*Hyper + IGH sep428q24.21*MYC*Hyper + IGH sep508q24.21*MYC*Hyper548q24.21*MYC*HyperCaseIGK partner chromosomePutative gene targetPrimary abnormality38q24.21*MYC*11;14418q24.21*MYC*Hyper + IGH sep4311q13.3*CCND1*Hyper468q24.21*MYC*Hyper588q24.21*MYC*HyperCaseIGL partner chromosomePutative gene targetPrimary abnormality411q13.3*CCND1*11;14228q24.21*MYC*4;14358q24.21*MYC*Hyper + IGH sep393q26.2*MECOM*Hyper + IGH sep458q24.21*MYC*Hyper5017q25.1*GRB2*Hyper558q24.21*MYC*Hyper568q24.22*ST3GAL1/NDRG1*Hyper618q24.22*ST3GAL1/NDRG1*Hyper638q24.22*ST3GAL1/NDRG1*HyperPartner genes associated with IGH, IGK, and IGL showing cytogenetic location and putative target genes. Hyper: Hyperdiploidy only. Hyper+IGH sep: Hyperdiploidy with IGH separationFig. 3Detection of additional abnormalities by MPseq in relation to each primary and secondary abnormality.In bold indicates primary abnormalities. Cytogenetic risk applied to all cases: H: high and S:standard. ND: Newly diagnosed, RR: relapsed/refractory.

There were five cases with IGK rearrangements (7.1% of cohort) mainly with partner chromosome 8q24.21 (*MYC*) (n = 4) and a single case with partner chromosome at 11q13.3 (*CCND1*) (Table [4](#Tab4){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}). In addition, 10 cases (14.3% of cohort) had IGL rearrangements with partner chromosomes at 8q24.21 (*MYC*) (n = 4), 11q13.3 (*CCND1*) (n = 1), 8q24.22 (n = 3) (putative target *ST3GAL1/NDRG1)*, 3q26.2 (*MECOM*) (n = 1) and 17q25.1 (*GRB2*) (n = 1) (Table [4](#Tab4){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}). Of these 15 cases with either an IGK or IGL rearrangement, 12 (80.0%) co-occurred with hyperdiploidy (hyperdiploidy only or hyperdiploidy with IGH separation).

We explored alterations in additional genes contributing to dysregulation of multiple pathways such as WNT or NF-kB signaling including genes *CYLD* at 16q12.1, *BIRC2* and *BIRC3* at 11q22,2, *NFKB1* at 4q24*, NFKB2* at 10q24.32, *TRAF2* at 9q34.3*, TRAF3 at 14q32.32* and *MAP3K14*/*NIK* at 17q21.31 or other tumor suppressor genes such as *CDKN2C* (p18) at 1p32.3 or *TENT5C/FAM46C* at 1p12^[@CR33],[@CR34]^ (Table [5](#Tab5){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}). Twenty-five cases (35.7%) had an alteration in *TENT5C/FAM46C* with 6 cases with translocations (five of these to *MYC*) and 19 cases had a heterozygous deletion of *TENT5C/FAM46C* ranging in size from 3.4 Mb to 120 Mb. Nineteen cases (27.1%) had alterations in *CDKN2C and/*or *FAF1*. Fourteen were heterozygous deletions involving *CDKN2C* ranging in size from 587 Kb to 120 Mb, four cases had focal biallelic *CDKN2C and FAF1* deletions (Supplemental Fig. [2A](#MOESM2){ref-type="media"}, case \#5) and one case had a heterozygous 655 Kb *FAF1* deletion without a *CDKN2C* deletion (Table [5](#Tab5){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}). Ten cases had deletions of *TRAF3* with 5 as heterozygous deletions and five as biallelic deletions (Supplemental Fig. [2B](#MOESM2){ref-type="media"}, case \#62) and a single case had a 92.9 Kb heterozygous deletion of *TRAF2* (Table [5](#Tab5){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}). Twenty-eight cases had deletions of *CYLD* (40% of cohort) with 24 cases having heterozygous deletions ranging in size from 634 Kb to 90.3 Mb with the majority representing large 16q deletions and four cases will smaller biallelic deletions (Table [5](#Tab5){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}, Supplemental Fig. [2C](#MOESM2){ref-type="media"}, case \#40). Additional alterations in *MAP3K14* were observed in four cases (three as heterozygous deletions and one as a 735 Kb gain), heterozygous deletion of *NFKB1* in seven cases, heterozygous deletion of *NFKB2* in 6 cases and a heterozygous and homozygous *BIRC2* and *BIRC3* deletions in two separate cases (Table [5](#Tab5){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}).Table 5Abnormalities of additional genes of clinical significanceCaseCYLDLocationBreakpointsSize (bp)Primary1HD16p13.3--16q24.30--903383459033834511;142HD16q11.2--16q24.346454000--903380004388400011;144HD16q11.2--16q24.346454000--903380004388400011;146HD16q11.2--16q24.346454000--903380004388400011;148HD16q11.2--16q24.346454000--903380004388400011;149HD16q21.1--16q24.350093000--891290003903600011;1415HD16q11.2--16q24.346454000--903380004388400011;1424**BD**16q12.1--16q12.150232040--5091302068098014;1625HD16q11.2--16q24.346454000--903380004388400014;1628HD16q11.2--16q24.346454000--903380004388400014;2029HD16q11.2--16q24.346454000--903380004388400014;2030HD16q11.2--16q24.346454000--903380004388400014;2033**BD**16q12.1--16q12.150777028--50812200351726;1435HD16q11.2--16q24.346454000--9033800043884000Hyper + IGH sep37HD16q11.2--16q24.346454000--9033800043884000Hyper + IGH sep40**BD**16q12.1--16q12.250376741--526308332254092Hyper + IGH sep41HD16q11.2--16q24.346454000--9033800043884000Hyper + IGH sep42HD16q12.1--16q12.150193000--50827000634000Hyper + IGH sep44HD16q11.2--16q24.346454000--9033800043884000Hyper48HD16q12.1--16q12.250123000--558380005715000Hyper49**BD**16q12.1--1612.150290162--51082053791891Hyper50HD16q11.2--16q24.346454000--9033800043884000Hyper52HD16q11.2--16q24.346454000--9033800043884000Hyper54HD16q11.2--16q24.346454000--9033800043884000Hyper61HD16q11.2--16q24.346454000--9033800043884000Hyper63HD16q11.2--16q24.346454000--9033800043884000Hyper66HD16q11.2--16q24.346454000--9033800043884000Tetraploid67HD16p13.3--16q24.30--9033834590338345Monosomy 13/14CaseBIRC2 and BIRC3LocationBreakpointsSize (bp)Primary6HD11q14.1--11q22.379621665--1089993462937768111;1421**BD**11q22.1--11q22.2101044665--10238930113446364;14CaseTENT5C/FAM46CLocationBreakpointsSize (bp)Primary5HD1p22.3--1p1287833886--1197074453187355911;146HD1p36.33--1p121--11999000011998999911;149HD1p35.3--1p1229234000--1199910009075700011;1415HD1p32.3--1p1251107000--1197610006865400011;1421HD1p31.1--1p1277992000--119733000417410004;1423HD1p34.2--1p1242342000--121700000793580004;1424HD1p13.3--1p12110882000--120028000914600014;1628HD1p32.1--1p1258536000--1199850006144900014;2029HD1p31.1--1p1275850000--1189340004308400014;2030Translocation to MYC1p12117855602N/A14;2032HD1p31.1--1p1270504000--119991000494870006;1433HD1p36.33--1p121--1199820001199819996;1434Translocation to MYC and MAFB1p12117611301;117746520N/AHyper + IGH sep35HD1p33--1p1249064000--11998900070925000Hyper + IGH sep37HD1p22.2--1p1289819000--11848300028664000Hyper + IGH sep40HD1p13.1--1p12116616000--1199900003374000Hyper + IGH sep53HD1p31.1--1p1277694018--11998300042288982Hyper56Translocation to MYC1p12117615759;117851083N/AHyper58Translocation to IL161p12117592488;117745524N/AHyper59Translocation to MYC1p12117670599N/AHyper60HD1p22.1--1p1292935000--11998100027046000Hyper61Translocation to MYC1p12117653222;117665080N/AHyper64HD1p31.3--1p1267860000--11859700050737000Hyper66HD1p36.33--1p121--119990000119989999Tetraploid67HD1p36.33--1p121--119991000119990999Monosomy 13/14CaseCDKN2C and FAF1LocationBreakpointsSize (bp)Primary5**BD**1p32.3--1p32.350884258--5101282512856711;146HD1p36.33--1p121--11999000011998999911;149HD1p35.3--1p1229234000--1199910009075700011;1410HD1p32.3--1p32.350402893--5098986758697411;1415**BD**1p32.3--1p32.350599579--5110676350718411;1421HD1p32.2--1p31.150276000--73879000236030004;1422**BD**1p32.3--1p32.350924750--50971658469084;1423HD1p34.2--1p1242342000--121700000793580004;1424HD FAF1 only1p33--1p32.349951000--5060600065500014;1633HD1p36.33--1p121--1199820001199819996;1434HD1p32.3--1p1250750000--11761100066861000Hyper + IGH sep35HD1p33--1p1249064000--11998900070925000Hyper + IGH sep40HD1p33--1p13.349723000--10923700059514000Hyper + IGH sep51HD1p33--1p31.350018770--6512548515106715Hyper52**BD**1p32.3--1p32.350925212--5100722182009Hyper58HD1p32.3--1p13.350467681--10751362757045946Hyper60HD1p34.1--1p32.245515071--550495389534467Hyper66HD1p36.33--1p121--119990000119989999Tetraploid67HD1p36.33--1p121--119991000119990999Monosomy 13/14CaseMAP3K14LocationBreakpointsSize (bp)Primary2HD17q21.31--17q21.3244943000--47142000219900011;1436HD17q21.31--17q21.3144583000--459820001399000Hyper + IGH sep44HD17p13.3--17q21.311--4573428745734286Hyper45Gain17q21.31--17q21.3145191000--45926000735000HyperCaseNFKB1 or NFKB2LocationBreakpointsSize (bp)Primary6HD NFKB14q13.2--4q2665930271--1159428835001261211;1423HD NFKB14p14--4q35.236402000--1898750001534730004;1433HD NFKB14p16.3--4q35.21--1902145551902145546;1434HD NFKB210q24.1--10q26.397005000--13379742236792422Hyper + IGH sep40HD NFKB14p16.3--4q35.21--190214555190214554Hyper + IGH sep44HD NFKB14q13.3--4q31.373221000--15052000077299000Hyper46HD NFKB210q24.32--10q24.33101899000--1033620001463000Hyper47HD NFKB210q24.32--10q24.32102148932--102721927572995Hyper51HD NFKB14p16.3--4q35.21--190214555190214554Hyper65HD NFKB210q24.32--10q25.1102399071--1042661761867105Hyper66HD NFKB14p16.3--4q35.21--190214555190214554Tetraploid66HD NFKB210p15.3--10q26.31--133797422133797421Tetraploid67HD NFKB210q11.21--10q26.342354000--13379742291443422Monosomy 13/14CaseTRAF2 or TRAF3LocationBreakpointsSize (bp)Primary8HD TRAF314q22.3--14q32.3356254000--1049900004873600011;1423HD TRAF314q11.2--14q32.3319958000--105864169859061694;1432**BD TRAF3**14q32.32--14q32.32102754161--102809688555276;1437HD TRAF314q24.3--14q32.3377344000--10559056328246563Hyper + IGH sep44HD TRAF314q21.1--14q32.3339707000--10704371867336718Hyper47HD TRAF314q32.32--14q32.32102845410--10290255057140Hyper52**BD TRAF3**14q32.32--14q32.32102722216--10279001367797Hyper60**BD TRAF3**14q32.32--14q32.32102741220--102888391147171Hyper62**BD TRAF3**14q32.31--14q32.32102680377--102913558233181Hyper67**BD TRAF3**14q32.32--14q32.32102841855--10287846336608Monosomy 13/1467HD TRAF29q34.3--9q34.3136828276--13692124192965Monosomy 13/14Case \#CRBN or IKZF1 or IKZF3LocationBreakpointsSize (bp)Primary8HD IKZF317q12--17q21.3135371000--44480000910900011;1417HD CRBN3p26.3--3p26.22738159--31948294566704;1422HD CRBN3p26.3--3q22.11--1305310001305309994;1428HD CRBN3p26.3--3p25.21--126590001265899914;2041HD CRBN3p26.3--3p24.11--2821300028212999Hyper + IGH sep44HD IKZF317p13.3--17q21.311--4573428745734286Hyper58HD CRBN3p26.3--3p26.11--71100007109999Hyper58IKZF1 Gain + insertion to 10q25.217p12.250207542--50430511222969HyperAbnormalities of genes of known clinical significance in MMLarge gains of chromosome material are not indicated*HD* heterozygous deletion, *BD* biallelic deletion indicated in bold, cytogenetic band and location in GRCh38

Evaluation for loss of function alterations of genes that have been associated with lenalidomide response or resistance (*CRBN*, *IKZF1* and *IKZF3*) identified 10.0% of the cohort had either a *CRBN*, *IKZF1* and *IKZF3* gene alteration (Table [5](#Tab5){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}, Supplemental Fig. [2D](#MOESM2){ref-type="media"}, case \#58). Specifically, five cases had a heterozygous deletion of *CRBN* ranging in size from 457 Kb to 130.5 Mb including case \#58 that had both a 7.1 Mb deletion encompassing *CRBN* and a 223 Kb *IKZF1* duplication with insertion of *IKZF1* into 10q25.2. Two cases had a heterozygous deletion that included *IKZF3* (9.1 Mb and 45.7 Mb).

Discussion {#Sec15}
==========

Most clinical laboratories employ FISH analysis of CD138 enriched plasma cells as the preferred methodology in order to identify recurrent primary and secondary genomic abnormalities of prognostic and therapeutic significance in patients with PCNs^[@CR15]^. The majority of these laboratories utilize only a limited FISH panel with many focusing on high risk abnormalities defined by the revised International Staging System (R-ISS) including 1q gain, t(4;14), t(14;16) or 17p deletion^[@CR15]^. Some laboratories have incorporated the use of chromosomal microarray analysis in the detection of CNAs such as hyperdiploidy, 17p deletions and 1q gains, however microarray studies are unable to identify balanced structural rearrangements necessitating the use of other methodologies in the detection of IGH rearrangements^[@CR15]^. It has also become increasingly apparent that some FISH probes, such as those targeting *MYC* rearrangements, display evidence of false negative results^[@CR18]--[@CR22]^. In addition, FISH panels for PCNs are variable between individual laboratories, provide a limited view of the whole genome and may not always reflect genomic complexity. Given that multiple research studies and investigational trials have used NGS based techniques to identify CNAs, SNVs along with structural rearrangements, we sought to explore the feasibility of employing an NGS technique in the detection of CNAs and structural rearrangements as a FISH replacement assay within a clinical genomics laboratory.

We describe the performance and added utility of a whole genome NGS based strategy, MPseq, in comparison to the current gold standard FISH approach in the evaluation of patients with PCNs. While MPseq and FISH displayed equal performance in the ability to classify the presence or absence of a recurrent, primary cytogenetic subtype (i.e. hyperdiploidy or specific IGH rearrangement), MPseq was superior compared to FISH in the characterization of rearrangement complexity, identification of secondary abnormalities, resolution of atypical FISH results and identification of novel abnormalities of prognostic significance not targeted by traditional FISH panels. Many samples chosen for this study had a high plasma cell burden (median 36% PCs) and \~33% of cases were obtained from fresh or frozen samples that did not require enrichment.

An advantage to using a whole genome NGS technique like MPseq is the ability to identify rearrangements using an unbiased approach. Other laboratories have developed and validated NGS methodologies utilizing target-enrichment approaches for PCNs allowing a custom target pull down of limited genomic regions^[@CR13],[@CR35]--[@CR37]^. While these targeted approaches have reduced cost and simplified analysis workflows, a genome wide approach utilizing long-insert whole genome sequencing employed by the MMRF CoMMpass Study in their Seq-FISH analysis has demonstrated improved sensitivity with similar specificity in relation to clinical FISH testing^[@CR38]^. Although MPseq is similar to Seq-FISH with regard to a whole genome sequencing approach, a significant limitation to the current MPseq strategy is the inability to identify SNVs. This limitation can be resolved with deeper and faster sequencing, coupled with reduced sequencing costs. An integrated genomic analysis incorporating structural variation, CNAs, and SNVs together may lead to enhanced prognostication^[@CR13]^. Of practical consideration is the \~two-fold increased cost and "turn-around-time" of reporting of clinical grade testing for MPseq compared to a comprehensive FISH panel; although we anticipate over time the cost and time of reporting for NGS approaches will continue to be reduced.

Another limitation to the use of MPseq is the inability to identify rearrangements in highly repetitive regions of the genome containing constitutive heterochromatin such as those involving telomeres, centromeres, and in regions near the centromeres of chromosomes 1, 9, and 16 and in the Y chromosome^[@CR27]^. This limitation may be reflected by the inability of MPseq to identify apparent trisomies in 2 cases (cases 5 and 42) with evidence of hyperdiploidy. Case 5 displayed a gain of a structurally abnormal chromosome 3 by conventional chromosome studies. Since the centromere regions that are targeted by the FISH probes are not covered by MPseq, it is unclear whether a small gain or presence of a polymorphism of these regions are present without evidence of a bona fide trisomy or whether the trisomy was present at a subclonal level below the limit of detection by MPseq (\<25% for CNAs)^[@CR18]^. Polymorphisms of the acrocentric chromosome 15 have also been reported^[@CR39]^ and are observed in FISH analysis of PCNs in our laboratory (data not shown). Discrepancies involving chromosome 15 are present in 6 of 70 cases in this study demonstrated by either a monosomy 15 FISH result with normal chromosome 15 s by MPseq or either a normal or monosomy 15 FISH result with trisomy 15 by MPseq. Since MPseq does not rely on detection of only the centromere region like FISH, analysis of copy number changes throughout the whole chromosome can be useful to interpret the presence or absence of a trisomy. On the other hand, any missed hyperdiploid cases may be of less relevance as hyperdiploidy can be detected by flow cytometric methods^[@CR40]^.

MPseq is not currently used in the detection of copy-neutral LOH or ploidy. As a result, MPseq did not identify any cases as tetraploid, an abnormality found in approximately 6% of patients with MM that has been associated with high-risk genomic abnormalities and with poor prognosis in NDMM^[@CR41]^. Six patients in our cohort had evidence of tetraploidy and 5 of these cases had tetraploidy in combination with high risk cytogenetics (Fig. [1](#Fig1){ref-type="fig"}), which were identified by MPseq. For case 39, it is unclear why MPseq failed to identify a 1q gain. No evidence of a duplication involving chromosome 1q (chr. 1:155122503--155571708) was identified by MPseq and based on FISH data, the 1q gain did not appear to be subclonal, however this sample was extracted from unsorted bone marrow with 20% clonal plasma cells which may have contributed to this missed abnormality. Subclonal CNAs and cases with low tumor load have a risk of being missed by MPseq, a risk that also exists when performing FISH.

Of the 30 discordant cases, 19 cases had abnormalities identified by MPseq that were missed by FISH, the majority involving insertional events near the *MYC* gene region. In total, *MYC* rearrangements were found in 51.4% of the cases in our cohort which includes NDMM and RRMM. This is consistent with previous reports identifying *MYC* rearrangements in 35% of NDMM with increased frequency in RRMM^[@CR10],[@CR42]^. *MYC* rearrangements have been reported as subclonal events and are associated with disease progression^[@CR3],[@CR11],[@CR43]^. Approximately 66% of *MYC* rearrangements have been found in association with non-Ig partners resulting in juxtaposition to enhancer sequences promoting aberrant *MYC* gene expression, which may be targeted by BRD4 inhibitors in MM^[@CR10]^. Identification of *MYC* rearrangements using a break-apart probe strategy resulted in a 50.0% false negative rate in our patient cohort. Whether these false negative insertion cases have the same prognostic implication as other *MYC* rearrangements remains unknown.

Two cases had deletions of the *TP53* gene region that were not identified by FISH. For cases 4 and 21, MPseq identified a deletion of *TP53* (5.6 Mb in case 4, 2.7 Mb in case 21). Interestingly, for case 21, MPseq also identified a translocation involving *TP53* (to 4q32.1). Both cases were scored as having two copies of *TP53* by FISH and represent false negative results due the location of the deletion in relation to the FISH footprint in case 4 and the *TP53* translocation in combination with the deletion in case 21. Although these cases had missed high risk abnormalities, the mSMART risk did not change since those cases also had additional high risk abnormalities \[1q gain for cases 4 and t(4;14) for case 21\]. For case 4, a separate NGS assay analyzing SNVs identified a pathogenic *TP53* mutation \[Chr17(GRCh37):g.7577111 G \> T; NM_001126113.2(TP53):c.827 C \> A; p.Ala276Asp\] located in the DNA-binding domain and in vitro functional data predicts that this variant results in non-functional p53 protein^[@CR44]^. *TP53* has been found to be mutated in 3--16% of NDMM^[@CR6],[@CR45]--[@CR47]^ with a higher frequency in RRMM^[@CR48]--[@CR50]^. *TP53* mutations in combination with 17p deletions are associated with double hit MM with reduced overall, progression-free and relapse-free survival^[@CR51]^. Therefore, this missed *TP53* deletion fails to identify the presence of a likely double hit MM in patient 4. The combination of a rearrangement and deletion also likely represents a double hit MM abnormality in case 21.

The *CCND1/IGH* dual color, dual fusion probe set is used to identify *CCND1/IGH* rearrangements. However, three copies of *CCND1* in the absence of IGH fusion can indicate trisomy 11 or non-IGH *CCND1* rearrangements. MPseq identified three *CCND1* rearrangements including case 4 (*IGL/CCND1*), case 43 (*IGK/CCND1*) described more fully in Peterson, et al.^[@CR52]^ and case 57 (*BRINP3/CCND1*). FISH also identified amplification of *CCND1* in case 4, three copies of *CCND1* in case 43 and a normal signal pattern for *CCND1* in case 57. The *CCND1* rearrangement identified in case 57 was a complex translocation between 1q31.1 and 11q13.3 consisting of four junctions and deletions of \~100 kb at both ends. Through this complex event, *CCND1* is brought into close proximity to the 3′ end of *BRINP3*, while the balancing set of junctions brings the 5′ end of *BRINP3* near 11q24.3. Additionally, the derivative chromosome containing *CCND1* has been copied. Overall this would result in three copies of *CCND1*, two of which have been translocated near the 3′ end of *BRINP3*. This case demonstrates how MPseq is able to determine complex rearrangements involving important genes without prior knowledge of the junction partner location.

Although immunoglobulin lambda rearrangements have been recently reported in association with poor prognosis^[@CR3]^, light chain rearrangements are typically not evaluated in the diagnostic work up of MM in most clinical genomics laboratories. Using MPseq data, we identify 10 cases (14.3% of entire cohort) with IGL rearrangements with five of these cases with standard risk cytogenetic results. IGL rearrangements and other focal deletions of clinical significance are typically not evaluated by FISH. Given the high rate of false-negative *MYC* rearrangements and inability to appreciate all abnormalities of clinical significance, we demonstrate that MPseq has increased clinical value compared to FISH in characterizing genomic abnormalities in PCNs.
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